Literature DB >> 23103446

Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?

Petr Kosztyu1, Petr Dolezel, Petr Mlejnek.   

Abstract

The effect of P-glycoprotein (P-gp, ABCB1, MDR1) expression on cell resistance to nilotinib was studied in human leukaemia cells. We used K562/Dox cells overexpressing P-gp and their variants (subclones) with a gradually decreased P-gp expression. These subclones were established by stable transfection of K562/Dox cells with a plasmid vector expressing shRNA targeting the ABCB1 gene. Functional analysis of P-gp using a specific fluorescent probe indicated gradually decreased dye efflux which was proportional to the P-gp expression. We observed that K562/Dox cells overexpressing P-gp contained a significantly reduced intracellular level of nilotinib when compared to their counter partner K562 cells, which do not express P-gp. This effect was accompanied by a decreased sensitivity of the K562/Dox cells to nilotinib. Importantly, cells with downregulated expression of P-gp gradually lost their ability to decrease the intracellular level of nilotinib although they still significantly decreased the intracellular level of daunorubicin (DNR). Accordingly, cells with the reduced expression of P-gp concomitantly failed to provide resistance to nilotinib, however, they exhibited a significant resistance to DNR. Taken together, we demonstrated that the conclusion as to whether P-gp is involved in nilotinib resistance or not strongly depends on its expression at protein level.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103446     DOI: 10.1016/j.phrs.2012.10.012

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

Review 1.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

2.  Transportation of berberine into HepG2, HeLa and SY5Y cells: a correlation to its anti-cancer effect.

Authors:  Yu-Nong Pang; Yin-Wen Liang; Tian-Shi Feng; Shuang Zhao; Hao Wu; Yu-Shuang Chai; Fan Lei; Yi Ding; Dong-Ming Xing; Li-Jun Du
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

3.  Apoptosis Induced by the Curcumin Analogue EF-24 Is Neither Mediated by Oxidative Stress-Related Mechanisms nor Affected by Expression of Main Drug Transporters ABCB1 and ABCG2 in Human Leukemia Cells.

Authors:  Nikola Skoupa; Petr Dolezel; Eliska Ruzickova; Petr Mlejnek
Journal:  Int J Mol Sci       Date:  2017-10-31       Impact factor: 5.923

4.  Detection of the Mitochondrial Membrane Potential by the Cationic Dye JC-1 in L1210 Cells with Massive Overexpression of the Plasma Membrane ABCB1 Drug Transporter.

Authors:  Katarina Elefantova; Boris Lakatos; Jana Kubickova; Zdena Sulova; Albert Breier
Journal:  Int J Mol Sci       Date:  2018-07-07       Impact factor: 5.923

5.  Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein.

Authors:  Hongping Min; Miaomiao Niu; Weilin Zhang; Jia Yan; Jiachang Li; Xiying Tan; Bo Li; Mengxiang Su; Bin Di; Fang Yan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

6.  MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Authors:  M Agrawal; B Hanfstein; P Erben; D Wolf; T Ernst; A Fabarius; S Saussele; D Purkayastha; R C Woodman; W-K Hofmann; R Hehlmann; A Hochhaus; M C Müller
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 7.  Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.

Authors:  Marialuisa Polillo; Sara Galimberti; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo
Journal:  Int J Mol Sci       Date:  2015-09-21       Impact factor: 5.923

Review 8.  Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.

Authors:  Dorte Lisbet Nielsen; Jesper Andreas Palshof; Nils Brünner; Jan Stenvang; Birgitte Martine Viuff
Journal:  Int J Mol Sci       Date:  2017-09-07       Impact factor: 5.923

9.  ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Authors:  Laura N Eadie; Phuong Dang; Jarrad M Goyne; Timothy P Hughes; Deborah L White
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

10.  Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4.

Authors:  Megumi Tsukamoto; Shiori Sato; Kazuhiro Satake; Mizuki Miyake; Hiroshi Nakagawa
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.